Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAT2A | P31153 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059742 | 0.80 | ALDH1A1 (0.60) | HTTALDH1A1 | |
| SCHEMBL3972355 | 0.79 | ALDH1A1 (0.66) | EP300KAT2BHTTALDH1A1CYP2E1 | |
| SCHEMBL15713999 | 0.79 | EP300 (0.46) | CYP11B2CYP11B1EP300KAT2BHTT | |
| SCHEMBL27251223 | 0.77 | ELANE (0.42) | HTTALDH1A1 | |
| SCHEMBL10059403 | 0.76 | EP300 (0.43) | CYP11B2EP300KAT2BHTTALDH1A1 | |
| SCHEMBL10079090 | 0.76 | TRPV1 (0.44) | EP300KAT2BHTTALDH1A1MAT2A | |
| SCHEMBL30977158 | 0.76 | ALDH1A1 (0.51) | EP300KAT2BHTTALDH1A1CYP2E1 | |
| SCHEMBL10059585 | 0.76 | CYP2A6 (0.50) | EP300KAT2BHTTALDH1A1CYP2E1 | |
| SCHEMBL27333035 | 0.75 | CYP19A1 (0.47) | CYP11B2CYP11B1EP300KAT2BHTT | |
| SCHEMBL31033090 | 0.74 | F7 (0.53) | EP300KAT2BHTTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590397-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |